Hansoh Pharmaceutical Group Company Limited (03378.HK) has been approved to conduct clinical trials of injection use HX111 in the People's Republic of China.

Intelligence Finance APP News, Hansi Etai-B (03378.HK) announced that the innovative drug injection HX111 developed by the company has been approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials within the territory of the People's Republic of China.